Effect of tamsulosin on ejaculatory function in BPH/LUTS

Sang Hoon Song, Hwancheol Son, Kwang Taek Kim, Sae Woong Kim, Du Geon Moon, Ki Hak Moon, Kwangsung Park, Jong Kwan Park, Sung Won Lee, Jae Seog Hyun, Nam Cheol Park

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4%. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P<0.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

Original languageEnglish
Pages (from-to)846-850
Number of pages5
JournalAsian Journal of Andrology
Volume13
Issue number6
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

tamsulosin
Reproductive Health
Incidence
Lower Urinary Tract Symptoms
Ejaculation
Pleasure
Prostate-Specific Antigen
Sexual Behavior
Prostate
Analysis of Variance
Cohort Studies
Logistic Models
Odds Ratio
Regression Analysis
Pain
Serum
Surveys and Questionnaires

Keywords

  • alpha-1 adrenergic receptors
  • benign prostatic hyperplasia
  • ejaculation
  • lower urinary tract symptom
  • Male Sexual Health Questionnaire
  • prostatic hyperplasia
  • tamsulosin

ASJC Scopus subject areas

  • Urology

Cite this

Song, S. H., Son, H., Kim, K. T., Kim, S. W., Moon, D. G., Moon, K. H., ... Park, N. C. (2011). Effect of tamsulosin on ejaculatory function in BPH/LUTS. Asian Journal of Andrology, 13(6), 846-850. https://doi.org/10.1038/aja.2011.25

Effect of tamsulosin on ejaculatory function in BPH/LUTS. / Song, Sang Hoon; Son, Hwancheol; Kim, Kwang Taek; Kim, Sae Woong; Moon, Du Geon; Moon, Ki Hak; Park, Kwangsung; Park, Jong Kwan; Lee, Sung Won; Hyun, Jae Seog; Park, Nam Cheol.

In: Asian Journal of Andrology, Vol. 13, No. 6, 01.11.2011, p. 846-850.

Research output: Contribution to journalArticle

Song, SH, Son, H, Kim, KT, Kim, SW, Moon, DG, Moon, KH, Park, K, Park, JK, Lee, SW, Hyun, JS & Park, NC 2011, 'Effect of tamsulosin on ejaculatory function in BPH/LUTS', Asian Journal of Andrology, vol. 13, no. 6, pp. 846-850. https://doi.org/10.1038/aja.2011.25
Song, Sang Hoon ; Son, Hwancheol ; Kim, Kwang Taek ; Kim, Sae Woong ; Moon, Du Geon ; Moon, Ki Hak ; Park, Kwangsung ; Park, Jong Kwan ; Lee, Sung Won ; Hyun, Jae Seog ; Park, Nam Cheol. / Effect of tamsulosin on ejaculatory function in BPH/LUTS. In: Asian Journal of Andrology. 2011 ; Vol. 13, No. 6. pp. 846-850.
@article{628bea7075fe4b95b1b866a1cecca926,
title = "Effect of tamsulosin on ejaculatory function in BPH/LUTS",
abstract = "This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4{\%}. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4{\%}, 3.1{\%}, 3.9{\%}, 3.9{\%}, 6.3{\%}, 7.1{\%} and 3.1{\%}, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P<0.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.",
keywords = "alpha-1 adrenergic receptors, benign prostatic hyperplasia, ejaculation, lower urinary tract symptom, Male Sexual Health Questionnaire, prostatic hyperplasia, tamsulosin",
author = "Song, {Sang Hoon} and Hwancheol Son and Kim, {Kwang Taek} and Kim, {Sae Woong} and Moon, {Du Geon} and Moon, {Ki Hak} and Kwangsung Park and Park, {Jong Kwan} and Lee, {Sung Won} and Hyun, {Jae Seog} and Park, {Nam Cheol}",
year = "2011",
month = "11",
day = "1",
doi = "10.1038/aja.2011.25",
language = "English",
volume = "13",
pages = "846--850",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of tamsulosin on ejaculatory function in BPH/LUTS

AU - Song, Sang Hoon

AU - Son, Hwancheol

AU - Kim, Kwang Taek

AU - Kim, Sae Woong

AU - Moon, Du Geon

AU - Moon, Ki Hak

AU - Park, Kwangsung

AU - Park, Jong Kwan

AU - Lee, Sung Won

AU - Hyun, Jae Seog

AU - Park, Nam Cheol

PY - 2011/11/1

Y1 - 2011/11/1

N2 - This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4%. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P<0.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

AB - This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4%. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P<0.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

KW - alpha-1 adrenergic receptors

KW - benign prostatic hyperplasia

KW - ejaculation

KW - lower urinary tract symptom

KW - Male Sexual Health Questionnaire

KW - prostatic hyperplasia

KW - tamsulosin

UR - http://www.scopus.com/inward/record.url?scp=80755127242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755127242&partnerID=8YFLogxK

U2 - 10.1038/aja.2011.25

DO - 10.1038/aja.2011.25

M3 - Article

C2 - 21785445

AN - SCOPUS:80755127242

VL - 13

SP - 846

EP - 850

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 6

ER -